

# Optical imaging perspective on the use of indocyanine green in endoscopic skull base neurosurgery

Preston D'Souza<sup>1</sup>, Alankar Kotwal<sup>1,4</sup>, Matias Costa<sup>1</sup>, Melisa Herrero Bocco<sup>1,4</sup>, Fernando Chiwo Gonzalez<sup>1,4</sup>, Patrick J. Karas<sup>1</sup>, Nisarg Shah<sup>3</sup>, Orly Coblens<sup>2</sup>, Scott Hardison<sup>2</sup>, Pablo A. Valdes<sup>1,4</sup>

<sup>1</sup>Department of Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA

<sup>2</sup>Department of Otolaryngology, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA

<sup>3</sup>Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA


<sup>4</sup>Department of Electrical Engineering, Rice University, Houston, Texas, USA

## Indocyanine Green: Key Advantages

- Fluorescence-guided surgery (FGS) has become a cornerstone in modern neurosurgery
- Indocyanine green (ICG) stands out given its optical profile
  - excitation/emission in the near-infrared (NIR) spectrum (780 and 805 nm, respectively),
  - deeper tissue penetration
  - favorable signal-to-noise ratios (SNR)
  - excellent safety profiles
- Advances include utilization in endoscopic endonasal skull base neurosurgery (ESS), neurovascular surgery, and 'second-window' ICG

## Institutional experience: ICG-endoscopic cases

Use of Indocyanine Green (ICG) in Endoscopic Endonasal Neurosurgery: Optical Properties and Operating Room Workflow



Case ID	Diagnosis / Variant	Age / Sex	Presentation	Approach	Extent of Resection	ICG Timing	Dose	Timing
1	Rathke cleft cyst	21F	Vision loss + hypercortisolism	Transsellar	GTR	ICG at beginning	6.25 mg	Immediate
2	Pituitary macroadenoma	54F	Acromegaly	Transsellar	Residual in left cavernous sinus	ICG at beginning	6.25 mg	Immediate
3	Pituitary macroadenoma	71 M	Vision loss	Transsellar	GTR	ICG beginning + mid-case to confirm gland	6.25 mg	Immediate
4	Pituitary macroadenoma	79 M	Visual loss	Transsellar	GTR	ICG at beginning	6.25 mg	Immediate
5	Pituitary macroadenoma	49 M	Vision loss	Transsellar + trans-tubercular	GTR	ICG beginning + mid-case for perforator assessment	6.25 mg	Immediate
6	Pituitary microadenoma	64F	Acromegaly	Transsellar	GTR	ICG at beginning	6.25 mg	Immediate
7	Pituitary macroadenoma	68 M	Tumor growth on serial imaging	Transsellar	GTR	ICG at beginning	6.25 mg	Immediate
8	Pituitary macroadenoma	67 M	Hypopituitarism + vision loss	Transsellar	GTR	ICG beginning + during case to identify gland	6.25 mg	Immediate

## Intraoperative visualization




Figure 1: A: ICG imaging of (+) fluorescent internal carotid arteries bilaterally as well as pituitary gland centrally, through the thin skull base; B: ICG imaging of (+) fluorescent pituitary gland, distinctly separating it from the non-fluorescent tumor; C: ICG imaging of (+) fluorescent pituitary and perforator vessels to the optic chiasm

## Conclusions

- Integrated workflow of ICG in endoscopic endonasal neurosurgery is efficient and safe
  - Intraoperative dosing regimens and imaging different timepoints can vary to select for key structures or pathology
- Optical properties of NIR light (i.e., low absorption, low scattering) allow high-resolution identification of key neurovascular structures
  - Signal penetration through bone
  - Real-time images of neurovascular structures
- Emerging technologies, such as quantitative fluorescence mapping, and hyperspectral imaging, hold potential to extend ICG use beyond just qualitative visualization

## References

1. Roberts DW, Valdés PA, Harris BT, et al. Glioblastoma Multiforme Treatment with Clinical Trials for Surgical Resection (Aminolevulinic Acid). *Neurosurgery Clinics of North America*. 2012;23(3):371-377. doi:10.1016/j.nec.2012.04.001
2. Valdés PA, Roberts DW, Lu FK, PhD, Golby A. Optical technologies for intraoperative neurosurgical guidance. *FOCUS*. 2016;40(3):E8. doi:10.3171/2015.12.FOCUS15550
3. Cho SS, Salinas R, Lee JYK. Indocyanine-Green for Fluorescence-Guided Surgery of Brain Tumors: Evidence, Techniques, and Practical Experience. *Front Surg*. 2019;6:11. doi:10.3389/fsurg.2019.00011
4. Schupper AJ, Rao M, Mohammadi N, et al. Fluorescence-Guided Surgery: A Review on Timing and Use in Brain Tumor Surgery. *Frontiers in Neurology*. 2021;12. doi:10.3389/fneur.2021.682151
5. Teng CW, Cho SS, Singh Y, et al. Second window ICG predicts gross-total resection and progression-free survival during brain metastasis surgery. *J Neurosurg*. 2021;135(4):1026-1035. doi:10.3171/2020.8.JNS201810
6. Lee JYK, Thawani JP, Pierce J, et al. Intraoperative Near-Infrared Optical Imaging Can Localize Gadolinium-Enhancing Gliomas During Surgery. *Neurosurgery*. 2016;79(6):856-871. doi:10.1227/NEU.0000000000001450
7. Olesrud I, Halvorsen IJ, Storaker MA, Heck A, Dahlberg D, Wiedmann MKH. Indocyanine green fluorescence in endoscopic transphenoidal resection of pituitary neuroendocrine tumors: a systematic review. *Acta Neurochir*. 2025;167(1):92. doi:10.1007/s00701-025-06500-z



**NASBS**  
North American Skull Base Society

